Dienogest - Comprehensive Research Paper

Document Version: 1.1 Last Updated: 2026-01-05 Classification: HRT Research - Female Progestins (Hybrid Estrane-Gonane) Paper Number: 40 of 76

1. Summary

1.1 Executive Summary

Dienogest (DNG) is a unique "hybrid" progestin that combines structural features of both 19-nortestosterone derivatives (estranes) and progesterone derivatives, giving it a distinctive pharmacological profile. Unlike most 19-nortestosterone progestins, dienogest has anti-androgenic activity and no androgenic effects, making it useful for treating both endometriosis and as part of oral contraceptives.

Key Distinguishing Features:

• Hybrid structure: Estrane backbone with cyanomethyl group (instead of ethinyl) at C17α
• Anti-androgenic: ~30% potency of cyproterone acetate (blocks androgen receptors)
• No androgenic activity: Unique among 19-nortestosterone derivatives
• No glucocorticoid or mineralocorticoid activity: Unlike some other progestins
• No SHBG binding: Does not displace testosterone from SHBG
• High oral bioavailability (>90%): Complete absorption
• Short half-life (~10 hours): No accumulation

Clinical Applications:

| Application | Products | Status | |---

Goal Relevance:

• Manage endometriosis symptoms for improved quality of life
• Reduce heavy menstrual bleeding to avoid anemia and improve daily functioning
• Use a birth control option that minimizes androgenic side effects like acne and unwanted hair growth
• Seek a contraceptive that includes natural estrogen for a more balanced hormonal approach
• Find a treatment for endometriosis that avoids the side effects of other hormone therapies
• Choose a birth control method with a lower risk of blood clots compared to combined oral contraceptives

----------|----------|--------| | Endometriosis treatment | Visanne (2 mg) | Approved in 100+ countries (NOT U.S.) | | Combined contraception | Natazia (E2V/DNG) | FDA-approved (U.S.) | | Heavy menstrual bleeding | Natazia | FDA-approved indication |

Safety Profile:

• Most common: Irregular bleeding (55%), headache (9%), breast discomfort (5%)
• BMD concern: Slight decrease (1-3%) with long-term use; reversible
• VTE risk: Lower than combined OCPs (progestin-only Visanne)
• Contraindicated: Active VTE, severe liver disease, hormone-sensitive cancers

Current Products:

1.2 Chemical and Pharmacological Classification

Chemical Name: 17α-Cyanomethyl-17β-hydroxy-estra-4,9-dien-3-one Molecular Formula: C₂₀H₂₅NO₂ Molecular Weight: 311.42 g/mol CAS Number: 65928-58-7

Classification:

• Drug Class: Progestin (synthetic progesterone analogue)
• Subclass: 19-Nortestosterone derivative (estrane) with hybrid features
• Generation: Fourth-generation progestin
• Structural Relationship: 19-Nortestosterone backbone with unique C17α modification
• Route: Oral

Structural Characteristics:

"Hybrid" Nature Explained:

Dienogest is called a "hybrid" because it combines:

• Estrane backbone (like norethindrone) → High oral bioavailability
• Properties of progesterone derivatives → Anti-androgenic, strong endometrial effect, no androgenic activity

1.3 Historical Background

Development Timeline:

• 1979: Dienogest first synthesized by Jenapharm (East Germany)
• 1995: Combined DNG/ethinyl estradiol oral contraceptive (Valette) approved in Germany
• 2007: Visanne (DNG 2 mg alone) approved in Japan for endometriosis
• 2009: Visanne approved in Europe for endometriosis
• 2010: Natazia (E2V/DNG) approved by FDA for contraception
• 2012: Natazia approved for heavy menstrual bleeding (HMB)
• 2019: Visanne approved in China for endometriosis
• Present: Approved in 100+ countries for endometriosis

Key Milestones:

1. First non-alkylated 19-norprogestin: Removes ethinyl group hepatic concerns
2. First progestin with both estrane structure and anti-androgenic activity: Unique combination
3. First quadriphasic OCP: Natazia introduced four-phase dosing concept
4. First OCP with estradiol valerate: Natazia uses bioidentical estrogen (not ethinyl estradiol)

1.4 Clinical Context and Rationale

Why Dienogest Is Unique:

1. Anti-androgenic 19-nortestosterone derivative: Only one in its class
2. Strong endometrial effect: Comparable to levonorgestrel for endometrial suppression
3. Moderate antigonadotropic effect: Comparable to cyproterone acetate
4. No SHBG displacement: Does not increase free testosterone
5. Effective for endometriosis: As effective as GnRH agonists without hypoestrogenic state

Clinical Positioning:

Comparison to Key Progestins:

2. Mechanism of Action

2.1 Molecular Mechanism

Progesterone Receptor Agonism:

Dienogest has relatively low binding affinity to the progesterone receptor (about 10% of progesterone) but exerts a very strong progestogenic effect on the endometrium, making it highly effective for endometrial suppression.

Mechanism of Endometrial Effects:

1. Decidualization: Transforms proliferative to secretory endometrium
2. Atrophy induction: Prolonged use causes endometrial atrophy
3. Anti-proliferative: Inhibits endometrial cell proliferation
4. Anti-angiogenic: Reduces new blood vessel formation in endometrium
5. Anti-inflammatory: Modulates inflammatory pathways in endometriotic lesions

Antigonadotropic Effects:

• Suppresses FSH and LH secretion
• Inhibits ovulation in most cycles at 2 mg/day
• Creates moderate hypoestrogenic environment (not as severe as GnRH agonists)
• Reduces endogenous estradiol production (to ~30-50 pg/mL)

2.2 Receptor Selectivity Profile

Binding Affinities:

*CPA = Cyproterone acetate

Anti-Androgenic Activity:

• Mechanism: Competitive antagonist at androgen receptors
• Potency: Approximately 30% that of cyproterone acetate
• Clinical effect: Reduces sebum production, improves acne, reduces hirsutism
• Note: Does NOT lower circulating testosterone (blocks receptor only)

Unique Among 19-Nortestosterone Progestins:

Dienogest is the only 19-nortestosterone derivative that is:

• Anti-androgenic (not androgenic)
• Free from androgenic side effects
• Has no binding to SHBG

2.3 Mechanism in Endometriosis

Direct Effects on Endometriotic Tissue:

Systemic Effects:

• Moderate estrogen suppression: Serum E2 reduced to 30-50 pg/mL
• Not severely hypoestrogenic: Unlike GnRH agonists (which reduce E2 to <20 pg/mL)
• Bone-sparing relative to GnRH agonists: Less BMD impact than leuprolide

Why Dienogest Works for Endometriosis:

1. Local effects on lesions: Direct anti-proliferative and anti-inflammatory
2. Systemic effects: Moderate estrogen suppression without severe hypoestrogenism
3. Continuous use: No breakthrough bleeding from cyclic withdrawal
4. Well-tolerated: Fewer side effects than GnRH agonists

2.4 Contraceptive Mechanisms (Natazia)

When combined with estradiol valerate in Natazia:

Quadriphasic Design Rationale:

Natazia uses four phases to:

1. Mimic natural cycle: Estrogen-dominant early, progestin-dominant late
2. Minimize breakthrough bleeding: Optimized hormone ratios
3. Allow use of estradiol valerate: More physiologic estrogen

2.5 Pharmacological Effects by System

Reproductive System:

Hypothalamic-Pituitary Axis:

• FSH: Moderate suppression
• LH: Moderate suppression
• Ovulation: Inhibited in ~95% of cycles at 2 mg/day

Metabolic Effects:

3. Indications and Uses

3.1 Regulatory-Approved Indications

Visanne (Dienogest 2 mg) - NOT U.S.:

1. Treatment of endometriosis - Europe, Japan, 100+ countries
   • Pain relief (dysmenorrhea, chronic pelvic pain)
   • Lesion size reduction
   • Long-term management

Natazia/Qlaira (E2V/DNG) - U.S. and International:

1. Prevention of pregnancy - FDA-approved
2. Treatment of heavy menstrual bleeding (HMB) - FDA-approved for women who choose OCP

3.2 Endometriosis Treatment (Visanne)

Efficacy:

Dosing:

• Standard dose: 2 mg once daily, continuously
• Timing: Any time of day, with or without food
• Duration: Can be used long-term (5+ years in studies)
• Start: Any day of cycle; use non-hormonal contraception

Why NOT FDA-Approved in U.S.:

• Bayer has not pursued FDA approval for Visanne
• Natazia (with estradiol valerate) is available in U.S.
• GnRH antagonists (elagolix/Orilissa) received FDA approval for endometriosis instead

3.3 Contraception (Natazia)

Formulation:

Efficacy:

3.4 Heavy Menstrual Bleeding (Natazia)

FDA Approval:

• First oral contraceptive approved for treatment of HMB
• Approved 2012

Efficacy:

• Significant reduction in menstrual blood loss
• Improvement in quality of life

Mechanism:

• Dienogest causes endometrial atrophy
• Thinner endometrium = less bleeding

3.5 Off-Label Uses

4. Dosing and Administration

4.1 Endometriosis (Visanne)

Standard Dosing:

Important Notes:

• NOT a contraceptive: Use non-hormonal birth control (condoms, copper IUD)
• Ovulation: Usually suppressed but not reliably
• Bleeding: Irregular bleeding common, especially first months

Missed Dose:

4.2 Contraception (Natazia)

Quadriphasic Regimen:

Administration:

• Take one tablet daily at same time
• Follow color sequence exactly
• Start new pack immediately after completing previous

Starting Natazia:

4.3 Dose Adjustments

Hepatic Impairment:

Renal Impairment:

• No dose adjustment required
• Minimal renal excretion

4.4 Special Considerations

Body Weight:

• No dose adjustment for body weight
• Efficacy maintained across weight ranges

Drug Interactions:

• Strong CYP3A4 inducers reduce dienogest levels
• See Section 7 for complete interactions

5. Pharmacokinetics and Pharmacodynamics

5.1 Absorption

Absorption Notes:

• Rapid and nearly complete absorption
• Peak levels within 2 hours
• No food restriction required
• High bioavailability due to minimal first-pass metabolism

5.2 Distribution

Distribution Notes:

• Exclusively bound to albumin (non-specific)
• Does NOT bind to SHBG - unlike most 19-nortestosterone progestins
• Lack of SHBG binding means:
  • No displacement of testosterone from SHBG
  • No prolongation of half-life via SHBG binding
  • Free testosterone levels not increased

5.3 Metabolism

Primary Pathways:

Key Metabolic Features:

• CYP3A4 is the primary enzyme responsible for metabolism
• Metabolites are pharmacologically inactive
• Metabolites are rapidly eliminated
• No CYP inhibition or induction by dienogest

CYP3A4 Interaction Potential:

5.4 Elimination

Clinical Implications:

• Short half-life requires once-daily dosing for continuous effect
• No accumulation with repeated dosing
• Steady-state reached within ~6 days
• Drug cleared within 2-3 days of discontinuation

5.5 Pharmacodynamic Effects

Endometrial Effects:

Ovulation Inhibition:

Note: Despite high ovulation inhibition, Visanne is NOT approved/marketed as contraception.

Estradiol Levels:

Dienogest creates a moderate hypoestrogenic state - enough to suppress endometriosis but not severe enough to cause menopausal symptoms or significant bone loss.

5.6 Pharmacokinetic Comparison

6. Side Effects and Safety Profile

6.1 Common Side Effects

Most Frequent (>10% incidence):

Bleeding Patterns:

6.2 Less Common Side Effects (1-10%)

*Note: Despite anti-androgenic effects, some patients report acne, possibly from baseline changes

6.3 Rare but Serious Side Effects (<1%)

Bone Mineral Density Changes:

• Mechanism: Moderate estrogen suppression affects bone
• Comparison: Less BMD loss than GnRH agonists
• Recommendation: BMD monitoring for long-term use (>2 years), especially in those with risk factors

Venous Thromboembolism (VTE):

• Progestin-only dienogest (Visanne) has minimal VTE risk
• Combined formulation (Natazia) carries typical COC-associated VTE risk

Hepatic Effects:

• Rare liver injury reported
• Contraindicated in severe liver disease
• Monitor LFTs if symptoms develop

6.4 Safety Signals and Concerns

Depression and Mood:

• 3-6% report depressed mood
• Pre-existing depression may worsen
• Advise patients to report mood changes
• Consider discontinuation if severe

Ovarian Cysts:

• Functional ovarian cysts occur in ~3%
• Usually resolve spontaneously
• Monitor if symptomatic

Weight Changes:

6.5 Comparative Safety

6.6 Post-Marketing Safety Data

Large-Scale Studies:

7. Drug Interactions

7.1 CYP3A4-Mediated Interactions

Dienogest is metabolized primarily by CYP3A4.

CYP3A4 Inducers (↓ Dienogest Levels):

CYP3A4 Inhibitors (↑ Dienogest Levels):

7.2 Specific Drug Interactions

Interaction Table:

7.3 Effect of Dienogest on Other Drugs

No Clinically Significant Effects On:

• CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4 substrates
• Dienogest does not induce or inhibit CYP enzymes

Specific Studies:

7.4 Natazia-Specific Interactions

When dienogest is combined with estradiol valerate (Natazia), additional interactions apply:

Estrogen Component Interactions:

7.5 Laboratory Interactions

Potential Interference:

7.6 Interaction Management Summary

High-Risk Interactions (AVOID):

• Rifampin, rifabutin
• St. John's Wort

Moderate-Risk (ALTERNATIVE CONTRACEPTION NEEDED):

• Carbamazepine, phenytoin, phenobarbital
• Efavirenz, nevirapine (non-boosted)

Low-Risk (MONITOR):

• Ketoconazole, itraconazole (monitor for side effects)
• Clarithromycin, erythromycin (usually tolerated)

No Significant Interactions:

• PPIs, H2 blockers
• Metformin, most antihypertensives
• SSRIs, SNRIs

8. Contraindications and Precautions

8.1 Absolute Contraindications

DO NOT USE Dienogest in:

8.2 Additional Contraindications (Natazia)

Combined OCP Contraindications Apply:

8.3 Precautions and Warnings

Use with Caution in:

8.4 Pre-Treatment Evaluation

Recommended Before Starting:

8.5 Reasons to Discontinue

Stop Dienogest Immediately If:

8.6 Product-Specific Warnings

Visanne (Dienogest Alone):

• Not a contraceptive - use backup
• Bone loss with long-term use
• Ectopic pregnancy risk if conception occurs

Natazia (E2V + DNG):

• All combined OCP warnings apply
• VTE risk increased (estrogen component)
• Arterial thrombosis risk
• Breakthrough bleeding common with missed pills

9. Special Populations

9.1 Pregnancy

Pregnancy Category: Not established (varies by country)

If Pregnancy Occurs on Dienogest:

• Stop medication immediately
• No evidence of need for termination
• Refer for prenatal counseling

9.2 Breastfeeding

Notes:

• Progestin-only dienogest (Visanne) compatible with breastfeeding
• Combined formulation (Natazia) should wait until lactation established
• Monitor infant for any unusual effects

9.3 Pediatric Patients

Adolescents (Post-Menarche to <18):

Pre-Menarche:

• Not indicated
• No data available

9.4 Geriatric Patients

Postmenopausal Women:

Note: Dienogest is primarily used in reproductive-age women for endometriosis or contraception. It is not a standard component of menopausal HRT regimens.

9.5 Hepatic Impairment

Monitoring: LFTs if symptoms of liver dysfunction (jaundice, RUQ pain)

9.6 Renal Impairment

Rationale: Dienogest undergoes hepatic metabolism; renal excretion is of inactive metabolites only.

9.7 Patients with Diabetes

Monitoring: Routine glucose monitoring; no additional monitoring required specifically for dienogest.

9.8 Patients with Depression

Important: 3-6% of patients report mood changes. Depressive symptoms should trigger re-evaluation.

9.9 Obesity

Notes:

• Progestin-only dienogest (Visanne) has minimal VTE risk regardless of weight
• Combined formulation (Natazia) has weight-related VTE risk (estrogen effect)
• Efficacy appears maintained across weight ranges

10. Monitoring and Follow-Up

10.1 Baseline Monitoring

Before Starting Dienogest:

10.2 Ongoing Monitoring

Routine Follow-Up:

10.3 Long-Term Monitoring

For Treatment >2 Years:

10.4 Monitoring for Specific Concerns

Bone Mineral Density:

If BMD Loss Documented:

• Ensure adequate calcium (1200 mg/day) and vitamin D (800-1000 IU/day)
• Consider lifestyle measures
• Reassess need for continued dienogest therapy
• Consider alternative treatments

10.5 When to Discontinue

Clinical Scenarios for Discontinuation:

10.6 Counseling Points

What to Tell Patients:

11. Cost and Accessibility

11.1 Brand vs. Generic

Visanne (Dienogest 2 mg):

Note: Visanne has no generic availability globally as of 2025.

Natazia (E2V/DNG):

11.2 Approximate Costs

Visanne (where available):

Natazia (U.S.):

11.3 Insurance Coverage

U.S. (Natazia Only):

For Endometriosis (Not Natazia indication):

• Natazia is NOT FDA-approved for endometriosis
• Off-label use may face coverage denial
• Prior authorization often required

11.4 Accessibility Issues

United States:

• Visanne is NOT available
• Patients seeking dienogest for endometriosis must use alternatives:
  • Norethindrone (generic, inexpensive)
  • Elagolix (Orilissa) - expensive, FDA-approved for endometriosis
  • GnRH agonists (leuprolide)

International:

• Visanne widely available in Europe, Asia, Latin America, Canada, Australia
• Often requires specialist prescription
• Generally affordable in countries with subsidized healthcare

11.5 Patient Assistance Programs

Bayer Patient Assistance:

Other Options:

• Hospital formulary access
• Clinical trial enrollment (limited)
• Import from international pharmacies (regulatory issues)

11.6 Cost Comparison

For Endometriosis Treatment:

For Contraception:

12. Clinical Evidence and Efficacy

12.1 Endometriosis: Pivotal Trials

Phase III Trial (vs. Leuprolide):

Conclusion: Dienogest non-inferior to leuprolide for pain reduction with fewer hypoestrogenic side effects.

12.2 Long-Term Efficacy Studies

Japanese 52-Week Extension:

European Long-Term Studies:

12.3 Contraception Efficacy (Natazia)

Pearl Index (Method Failure Rate):

Note: Higher typical-use Pearl Index reflects complex quadriphasic regimen and sensitivity to missed pills.

12.4 Heavy Menstrual Bleeding (Natazia)

Phase III Trial:

FDA Approval Basis:

• First OCP approved for HMB (2012)
• Demonstrated significant reduction in menstrual blood loss

12.5 Comparison Studies

Dienogest vs. Other Progestins for Endometriosis:

Dienogest vs. GnRH Agonists:

12.6 Meta-Analyses and Systematic Reviews

Cochrane Review Findings:

Key Meta-Analysis Results:

12.7 Real-World Evidence

Post-Marketing Studies:

Patient Satisfaction:

13. Comparison to Alternatives

13.1 Dienogest vs. Other Progestins

Structural and Pharmacological Comparison:

13.2 For Endometriosis Treatment

Treatment Options Comparison:

When to Choose Dienogest:

1. Need long-term treatment: Better tolerated than GnRH agonists
2. Hot flash concern: Minimal compared to GnRH agonists
3. BMD concerns: Less impact than leuprolide
4. Anti-androgenic benefit desired: Acne/hirsutism improvement
5. Oral preference: Vs. injectable or IUD

When to Choose Alternatives:

1. U.S. patient: Visanne not available; use norethindrone or elagolix
2. Need contraception: Natazia (combined) or other COC
3. Severe symptoms: May need GnRH agonist initially
4. Long-acting preferred: LNG-IUD or DMPA

13.3 For Contraception

Natazia vs. Other COCs:

When to Choose Natazia:

1. Heavy menstrual bleeding: FDA-approved
2. Preference for natural estrogen: E2V vs. EE
3. Anti-androgenic need: Dienogest helps acne/hirsutism
4. EE side effects: Alternative to ethinyl estradiol

When to Choose Alternatives:

1. PMDD: Yaz is FDA-approved
2. Cost concern: Generic levonorgestrel/EE is much cheaper
3. Simpler regimen: Monophasic pills easier to manage
4. Missed pill tolerance: Drospirenone (Slynd POP) has 24-hour window

13.4 Dienogest in Combination Products

Available Combinations:

Monotherapy:

13.5 Decision Algorithm

For Endometriosis:

U.S. Patient?
├── YES → Visanne not available
│   ├── Mild symptoms → Norethindrone 5 mg (cheap, effective)
│   ├── Moderate symptoms → DMPA or LNG-IUD
│   └── Severe/refractory → Elagolix or GnRH agonist
│
└── NO (International) → Dienogest (Visanne) appropriate first-line
    ├── Good response → Continue long-term
    └── Inadequate response → Add surgery or switch to GnRH agonist

For Contraception:

Need anti-androgenic effect?
├── YES →
│   ├── Also need HMB treatment → Natazia
│   ├── Also have PMDD → Yaz (drospirenone)
│   └── Cost concern → Generic drospirenone or norethindrone
│
└── NO → Generic levonorgestrel/EE (cheapest, effective)

14. Storage and Handling

14.1 Storage Requirements

Visanne:

Natazia:

14.2 Shelf Life

After Opening:

• Use within expiration date on blister
• Discard if tablets appear damaged or discolored

14.3 Dispensing Information

Packaging:

Natazia Color Coding:

14.4 Patient Instructions

Storage at Home:

1. Store at room temperature (avoid bathroom/kitchen humidity)
2. Keep in original blister pack until use
3. Keep away from children
4. Do not use after expiration date

Handling:

• Take tablet with water
• Can be taken with or without food
• Swallow whole; do not crush or chew
• If dropped, may still be used if intact

14.5 Travel Considerations

International Availability:

• Visanne may not be available in all countries
• Natazia (Qlaira) available under different names in Europe
• Carry prescription documentation for customs

14.6 Disposal

Proper Disposal:

1. Do not flush medications
2. Use drug take-back programs if available
3. If no take-back available:
   • Mix with coffee grounds or cat litter
   • Place in sealed container
   • Dispose in household trash

15. Goal Archetype Integration

15.1 Progestin Goal Archetype

Dienogest serves specific user goals within the Progestin Goal Archetype, which encompasses individuals seeking progesterone-like hormonal support for various clinical objectives.

Primary Goal Alignments:

Goal-Specific Considerations:

Progestin Selection Matrix:

15.2 Endometriosis Goal Archetype

The Endometriosis Goal Archetype represents individuals whose primary objective is managing endometriosis symptoms while minimizing treatment side effects and preserving fertility options.

Archetype Profile:

Dienogest's Archetype Fit:

Archetype-Driven Treatment Selection:

Endometriosis Patient Assessment:

Step 1: Severity Assessment
├── Mild symptoms → NSAIDs + hormonal contraception
├── Moderate symptoms → Dienogest (if available) or Norethindrone
└── Severe symptoms → GnRH agonist/antagonist or surgery

Step 2: Geographic Availability
├── Outside U.S. → Dienogest (Visanne) first-line
└── Inside U.S. → Norethindrone (cheap) or Elagolix (expensive)

Step 3: Comorbidity Check
├── Androgenic symptoms (acne, hirsutism) → Dienogest preferred
├── Depression history → Monitor closely; consider alternatives
├── Osteoporosis risk → Short course or add bone protection
└── VTE history → Visanne OK (progestin-only); avoid Natazia

User Goal Statements Mapped to Dienogest:

15.3 Combined Archetype Scenarios

Scenario 1: Young Woman with Endometriosis + Acne

Scenario 2: Perimenopausal Woman with HMB

Scenario 3: Woman with Endometriosis + Depression History

16. Age-Stratified Dosing

16.1 Dosing Principles by Age

Dienogest dosing is generally consistent across ages, but clinical considerations vary significantly by life stage.

Age-Based Overview:

16.2 Adolescent Dosing (<18 Years)

Clinical Context:

• Endometriosis increasingly recognized in adolescents
• BMD acquisition ongoing; any suppression is concerning
• Limited clinical trial data in this population

Dosing Protocol:

Special Considerations:

Evidence:

• No dedicated adolescent trials for dienogest
• Extrapolated from adult data and clinical experience
• ESHRE guidelines support progestin use in adolescents with endometriosis

16.3 Reproductive Age Dosing (18-35 Years)

Clinical Context:

• Primary age group for dienogest use
• Fertility preservation important
• Longest expected treatment duration

Dosing Protocol:

Fertility Considerations:

16.4 Late Reproductive Age Dosing (35-45 Years)

Clinical Context:

• Increasing VTE risk with age
• Perimenopause may begin
• Endometriosis symptoms may intensify or improve

Dosing Protocol:

Age 35-45 Decision Tree:

Age 35-45 with Endometriosis:

Smoker (≥15 cig/day)?
├── YES → Visanne only (progestin-only); Natazia contraindicated
└── NO → Either product acceptable

VTE Risk Factors Present?
├── Multiple factors → Visanne preferred; careful monitoring
└── Low risk → Natazia OK if contraception desired

Perimenopause Suspected?
├── YES → FSH testing; consider Natazia for cycle regularity
└── NO → Continue current regimen

16.5 Perimenopausal Dosing (45-55 Years)

Clinical Context:

• Endometriosis often improves with declining estrogen
• HMB may worsen before menopause
• Transition to menopause needs planning

Dosing Protocol:

Transition Protocol:

Menopausal Transition Considerations:

• Check FSH during placebo week (Natazia) or after 2-week washout (Visanne)
• Symptoms of menopause may emerge as dienogest is stopped
• Standard menopausal HRT (estrogen + progestin) differs from dienogest protocols

16.6 Postmenopausal Considerations (>55 Years)

Clinical Context:

• Dienogest is NOT a standard component of menopausal HRT
• Endometriosis should be quiescent postmenopause
• No indication for new starts in this age group

When Dienogest Might Be Considered:

Recommendation: Dienogest has no established role in postmenopausal women. Standard menopausal HRT uses other progestins (micronized progesterone, MPA, norethindrone acetate).

16.7 Age-Stratified Monitoring Summary

17. Drug Interactions (Expanded)

17.1 Comprehensive Interaction Reference

Building on Section 7, this section provides expanded clinical guidance for managing drug interactions.

Critical Interaction Categories:

17.2 Detailed CYP3A4 Inducer Interactions

Strong Inducers (AVOID):

Moderate Inducers (CAUTION):

17.3 Detailed CYP3A4 Inhibitor Interactions

Strong Inhibitors (MONITOR):

Side Effects to Monitor with CYP3A4 Inhibitors:

17.4 Hormonal Contraception-Specific Interactions

Interactions Affecting Natazia (Combined OCP):

Lamotrigine-Specific Protocol:

Patient on Lamotrigine Starting Natazia:

1. Baseline lamotrigine level
2. Start Natazia
3. Check lamotrigine level at 2 weeks
4. Expect ~50% decrease in lamotrigine levels
5. Adjust lamotrigine dose to maintain therapeutic level
6. During pill-free interval: lamotrigine levels rise
7. Consider continuous Natazia use to avoid fluctuations

If Stopping Natazia in Patient on Lamotrigine:
1. Expect lamotrigine levels to rise
2. Monitor for toxicity (ataxia, diplopia, nausea)
3. May need lamotrigine dose reduction

17.5 Supplement and Herbal Interactions

17.6 Interaction Management Algorithms

For Epilepsy Patients:

Epilepsy Patient Needing Endometriosis Treatment:

On Enzyme-Inducing AED (phenytoin, carbamazepine, phenobarbital)?
├── YES → Dienogest NOT reliable
│   ├── Alternative: LNG-IUD (local effect, not affected)
│   ├── Alternative: DMPA 150 mg + short injection interval
│   └── Alternative: Non-hormonal (surgery, NSAIDs)
│
└── NO (on levetiracetam, lamotrigine, valproate)
    ├── Visanne OK at standard dose
    └── Natazia: Watch lamotrigine interaction

For HIV Patients:

HIV Patient Needing Dienogest:

On Efavirenz or Nevirapine?
├── YES → Dienogest levels reduced 40-60%
│   ├── Add barrier method
│   └── Consider LNG-IUD or DMPA
│
On Ritonavir-Boosted PI?
├── Could ↑ or ↓ dienogest (complex)
│   └── HIV specialist consultation required
│
On Integrase Inhibitors (DTG, BIC)?
├── Minimal interaction expected
└── Dienogest OK at standard dose

18. Bloodwork Impact

18.1 Expected Laboratory Changes

Dienogest therapy produces predictable changes in hormonal and metabolic parameters.

Hormonal Panel Changes:

18.2 Metabolic Panel Impact

Lipid Profile:

Glucose Metabolism:

Hepatic Parameters:

18.3 Coagulation Impact

Coagulation Parameters:

Clinical Interpretation:

• Visanne (progestin-only): Minimal to no impact on coagulation
• Natazia (combined): Typical COC-associated changes; VTE risk increased

18.4 Bone Markers

Bone Turnover Markers:

BMD Correlation:

18.5 Recommended Monitoring Schedule

Baseline Bloodwork (Before Starting):

Ongoing Monitoring:

18.6 Abnormal Results and Management

Hormonal Panel Abnormalities:

Metabolic Panel Abnormalities:

Bone Health Concerns:

18.7 Laboratory Assay Interference

Potential Assay Cross-Reactivity:

If Progesterone Measured:

• Inform lab of dienogest use
• Consider LC-MS/MS method for accurate progesterone measurement
• Low progesterone expected (suppressed endogenous production)

19. Protocol Integration (Endometriosis Treatment)

19.1 Endometriosis Treatment Framework

Dienogest fits within a comprehensive endometriosis management protocol that includes medical therapy, surgical options, and supportive care.

Treatment Phases:

19.2 First-Line Treatment Protocol

Empiric Treatment (Without Surgical Diagnosis):

For patients with suspected endometriosis based on symptoms:

Initiation Protocol:

Starting Dienogest for Endometriosis:

Pre-Treatment:
├── Confirm not pregnant (β-hCG)
├── Document baseline symptoms (VAS pain scale)
├── Review contraindications
├── Counsel on bleeding patterns
└── Discuss contraception need (Visanne NOT reliable)

Day 1 (Any cycle day):
├── Start dienogest 2 mg once daily
├── Same time each day
└── With or without food

Week 1-4:
├── Expect irregular bleeding/spotting
├── Pain may not improve immediately
└── Continue analgesics as needed

Month 1-3:
├── Bleeding usually most problematic
├── Pain typically begins improving
└── Schedule follow-up at month 3

Month 3 Assessment:
├── Pain improvement? → Continue
├── Intolerable bleeding? → Reassess; may improve
├── No improvement? → Consider imaging; surgical evaluation
└── Side effects? → Manage or consider alternative

19.3 Post-Surgical Protocol

After Conservative Surgery (Excision/Ablation):

Dienogest prevents recurrence after surgical treatment.

Evidence for Post-Surgical Use:

• Recurrence rate with dienogest: ~5-10% at 2 years
• Recurrence rate without treatment: ~30-50% at 2 years
• Dienogest maintains surgical benefits

Post-Surgical Protocol:

Post-Surgical Dienogest Initiation:

Surgery Day:
└── No dienogest (NPO)

Post-Op Day 1-2:
├── If tolerating oral intake → Start dienogest 2 mg
└── If nausea/vomiting → Delay until tolerating food

Post-Op Week 1:
├── Continue dienogest daily
├── Expect some irregular bleeding (surgical + hormonal)
└── Pain control with analgesics

Post-Op Month 1:
├── Follow-up visit
├── Assess wound healing
├── Continue dienogest
└── Discuss long-term plan

Post-Op Month 3-6:
├── Assess symptom control
├── Consider imaging if symptoms recur
└── Plan for long-term management

19.4 Long-Term Maintenance Protocol

5+ Year Management:

Dienogest is suitable for long-term use with appropriate monitoring.

Long-Term Management Checklist:

19.5 Protocol for Fertility Planning

When Pregnancy Desired:

Fertility Timeline:

Fertility Planning with Endometriosis:

Currently on Dienogest:
├── Symptoms well-controlled
├── Desire pregnancy in future
└── Continue dienogest until ready

Ready to Conceive:
├── Stop dienogest
├── Fertility returns within 1-2 cycles
├── Begin TTC
└── No washout period required

TTC Unsuccessful After 6 Months:
├── Fertility evaluation (both partners)
├── Consider HSG, semen analysis
├── May need IVF given endometriosis
└── Dienogest NOT used during fertility treatment

Post-Pregnancy Options:
├── Breastfeeding: Dienogest (Visanne) compatible
├── Not breastfeeding: Dienogest or Natazia
└── Restart when appropriate

19.6 Switching Protocols

Switching FROM Dienogest:

Switching TO Dienogest:

19.7 Treatment Failure Protocol

Defining Treatment Failure:

Treatment Failure Algorithm:

Dienogest Treatment Failure:

Step 1: Confirm Compliance
├── Taking daily as prescribed?
├── Drug interactions reducing efficacy?
└── If non-compliant → Educate and retry

Step 2: Assess Type of Failure
├── Pain persists → May need surgical evaluation
├── Bleeding intolerable → May improve with time; reassess at 6 months
├── Mood effects → Consider discontinuation; try alternative
└── Lesions progressing → Surgical consultation

Step 3: Consider Alternatives
├── GnRH agonist (leuprolide) → Short-term; add-back therapy
├── GnRH antagonist (elagolix) → Oral; U.S. available
├── Surgical excision → For deep/large lesions
├── LNG-IUD → Local progestin; fewer systemic effects
└── Combination approach → Surgery + medical suppression

19.8 Integrated Care Team Protocol

Multidisciplinary Approach:

Communication Protocol:

Annual Review Communication:

Gynecologist → Primary Care:
├── Current dienogest regimen
├── Any side effects noted
├── Recommended monitoring
└── Follow-up plan

Primary Care → Gynecologist:
├── BP, weight trends
├── Mood screen results
├── Any new medications (interactions)
└── Metabolic panel if obtained

20. References

15.1 Prescribing Information

1. Visanne Prescribing Information (Bayer). European Medicines Agency approved product information. Current version.

2. Natazia Prescribing Information (Bayer). U.S. FDA approved label. Current version. Available at: FDA.gov

3. Qlaira Summary of Product Characteristics (Bayer). European version of Natazia.

15.2 Key Clinical Trials

1. Strowitzki T, et al. (2010). "Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial." Human Reproduction, 25(3):633-641.

2. Momoeda M, et al. (2009). "Long-term use of dienogest for the treatment of endometriosis." Journal of Obstetrics and Gynaecology Research, 35(6):1069-1076.

3. Petraglia F, et al. (2012). "Patient-reported outcomes among women with endometriosis treated with dienogest: results from a 52-week extension study." Journal of Minimally Invasive Gynecology, 19(Suppl):S7.

4. Fraser IS, et al. (2011). "A randomized controlled trial comparing the efficacy, safety, and tolerability of E2V/DNG oral contraceptive versus placebo in women with heavy menstrual bleeding." Contraception, 83(4):354-361.

15.3 Pharmacology and Pharmacokinetics

1. Oettel M, et al. (1999). "Dienogest: pharmacokinetic properties." Drugs Today, 35(Suppl C):3-12.

2. Sasagawa S, et al. (2008). "Pharmacological profile of dienogest." Journal of Steroid Biochemistry and Molecular Biology, 102(1-5):142-148.

3. Kuhl H. (2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration." Climacteric, 8(Suppl 1):3-63.

15.4 Endometriosis Treatment Reviews

1. Vercellini P, et al. (2016). "Progestins for symptomatic endometriosis: a critical analysis of the evidence." Fertility and Sterility, 106(7):1552-1571.

2. Murji A, et al. (2020). "Progestins and Endometriosis: A Review." Journal of Obstetrics and Gynaecology Canada, 42(7):870-878.

3. Dunselman GA, et al. (2014). "ESHRE guideline: management of women with endometriosis." Human Reproduction, 29(3):400-412.

15.5 Safety and Long-Term Data

1. Römer T, et al. (2016). "Long-term treatment of endometriosis with dienogest: results from an open-label 52-week extension study." Journal of Endometriosis and Pelvic Pain Disorders, 8(3):89-97.

2. Momoeda M, et al. (2014). "Long-term use of dienogest for the treatment of endometriosis." Journal of Obstetrics and Gynaecology Research, 40(6):1621-1627.

3. European Medicines Agency. "Visanne: EPAR - European Public Assessment Report." Available at: EMA.europa.eu

15.6 Comparison and Review Articles

1. Bayer Healthcare. "Dienogest: Pharmacological Profile and Clinical Evidence." Internal publication, 2015.

2. Ruan X, et al. (2012). "The pharmacology of dienogest." Maturitas, 71(4):337-344.

3. Schindler AE. (2011). "Dienogest in long-term treatment of endometriosis." International Journal of Women's Health, 3:175-184.

15.7 Guidelines and Consensus Statements

1. ESHRE Guideline on Endometriosis (2022). European Society of Human Reproduction and Embryology. Available at: ESHRE.eu

2. ACOG Practice Bulletin No. 114 (2010, reaffirmed 2020). "Management of Endometriosis." American College of Obstetricians and Gynecologists.

3. CDC U.S. Medical Eligibility Criteria for Contraceptive Use (2016, updated 2020). Centers for Disease Control and Prevention.

15.8 Additional Resources

1. Endometriosis.org - Patient information and support

2. Bayer Healthcare Product Information - www.bayer.com

3. UpToDate - "Endometriosis: Treatment of pelvic pain"

4. DailyMed (NIH) - Natazia drug label: dailymed.nlm.nih.gov

Document Information

Version History:

Authors:

• Research compilation for EpiqAminos product knowledge base

Reviewers:

• Pending clinical review

Next Review Date: 2026-06-26

Document Completion: 2025-12-26 Status: PAPER 40 OF 76 COMPLETE Next Paper: #41 - Climara Pro (Estradiol/Levonorgestrel)